In patients with acute coronary syndrome, dual antiplatelet therapy with aspirin and a P2Y 12 inhibitor like prasugrel is prescribed for one year. Here, we investigated how the hemostatic function of platelets recovers after discontinuation of prasugrel treatment. Therefore, sixteen patients who suffered from ST-elevation myocardial infarction were investigated. Patients were treated with aspirin (100 mg/day, long-term) and stopped taking prasugrel (10 mg/day) after one year. Blood was collected at the last day of prasugrel intake and at 1, 2, 5, 12 and orange and the novel 5'Cy5-oligo-dT probe revealed that this subpopulation consisted of juvenile platelets, which progressively contributed to platelet aggregation and thrombus formation under flow. During offset, juvenile platelets were overall more reactive than older platelets. Interestingly, the responsiveness of both juvenile and older platelets increased in time, pointing towards a residual inhibitory effect of prasugrel on the megakaryocyte level. In conclusion, the gradual increase in thrombogenicity after cessation of prasugrel treatment is due the increased activity of juvenile platelets.
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Introduction
The autocrine mediator ADP is a moderately strong platelet agonist, stimulating platelet aggregation and thrombus formation and contributing to thrombus stabilization. 1 At present, the ADP receptor P2Y 12 is one of the most effective targets for antiplatelet therapy, i.e. by clopidogrel, prasugrel, and ticagrelor. 2, 3 Clopidogrel in combination with aspirin has been the standard therapy over the last decade to prevent recurrent atherothrombotic complications in patients who had a myocardial infarction. 4 More recently, prescription of prasugrel or ticagrelor instead of clopidogrel is increasingly recommended following publication of the TRITON and PLATO studies, which demonstrated a net clinical benefit over clopidogrel on top of aspirin, due to a higher degree of platelet inhibition. [4] [5] [6] [7] [8] [9] The thienopyridines clopidogrel and prasugrel are both prodrugs, which require metabolic conversion to form an active metabolite that irreversibly interacts with the P2Y 12 receptors of circulating platelets. 10 In contrast, ticagrelor is a reversible, non-competitive P2Y 12 antagonist -belonging to the cytopentyl-triazolo class of pyrimidines -interacting with the platelet receptors without metabolic conversion. [10] [11] [12] Due to the irreversible inhibition of the platelet P2Y 12 receptors by the active metabolites of clopidogrel and prasugrel, the formation of new platelets is required to recover platelet function. 7, 9 After ticagrelor treatment, recovery of platelet function is only determined by the elimination time of the drug (half-life of 8 hours). 10 There is limited evidence that during the offset period of irreversible P2Y 12 inhibitors (usually prescribed for one year)
patients may have an increased risk of a recurrent myocardial event. [13] [14] [15] [16] [17] This may point to hyperactivity of the newly formed platelets in the offset period, although the mechanism is unclear.
Previous experiments with rats have indicated that stopping clopidogrel treatment resulted in the sudden appearance of a population of fully responsive platelets, whereas recovery from ticagrelor treatment led to a more gradual regain in function of all platelets. 18 The newly formed, juvenile platelets with active P2Y 12 receptors seemed to preferentially incorporate into thrombi generated under flow conditions. 18 Juvenile platelets, also described as reticulated platelets because of the presence of reticular-bound mRNA, are those platelets that are shed most recently from the megakaryocytes in the bone marrow. [19] [20] [21] Due to the gradual degradation of mRNA, they form only a small part of the entire platelet population. Only little is known about the properties of reticulated platelets, although incidental studies report on a larger size with more granules, 22 and a high reactivity towards platelet agonists. 23, 24 With a Sysmex analyzer, using cell-permeant fluorescent mRNA dyes containing polymethine and oxazine, or using the mRNA probe thiazole orange, evidence has been obtained that patients with more reticulated platelets respond less effective to clopidogrel or prasugrel medication.
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In the present study, we investigated how the hemostatic function of platelets recovers after discontinuation of prasugrel treatment. We hypothesized an immediate recovery of newly formed, juvenile platelets to the level of untreated platelets. Our data provide evidence for a critical role of the juvenile platelets in the regained aggregation of platelets and thrombus formation, and also show that these platelets gradually increase in responsiveness.
Methods
For a detailed description of the methods, please see the supplementary material.
Patients and control subjects
This study was approved by the local medical ethics committee (MEC 12-3-075). All patients and healthy volunteers gave written informed consent for participation according to the Helsinki declaration. Sixteen patients were studied who were treated with prasugrel (10 mg/day) for one year and long-term aspirin (80-100 mg/day) due to a myocardial infarction with ST elevation. After one year of prasugrel treatment, blood was collected on the last treatment day, and at 1, 2, 5 and 30 days later. From two patients, blood samples were also Juvenile platelets were identified using two different methods of mRNA staining, i.e.
with thiazole orange 34 or by a novel method using Cy5-labeled oligo-dT, which binds to the poly-A tail of mRNA species. Thiazole orange (15% in filtered PBS) was added to PRP, according to established procedures. 34 Samples were activated with 2MeS-ADP in the presence of AF647-fibrinogen. For staining with 5'Cy5-oligo-dT, washed platelets were activated with 2MeS-ADP in the presence of OG488-fibrinogen. Samples were fixed with 0.2% formaldehyde, permeabilized with 0.1% saponin and subsequently incubated with 5'-Cy5-oligo-dT at 37 °C. For all samples, 5'Cy5-oligo-dA was used as a negative control probe to check for specificity of the staining. Color compensation was not required as fluorescent spectra did not overlap.
The average percentage of juvenile platelets as analyzed by the thiazole orange staining and the oligo-dT staining was 6.7% (± 1.9%) and 21.5% (± 5.8%) respectively. The discrepancy in the percentage of detected juvenile platelets can be explained by the higher sensitivity of the oligo-dT staining to detect mRNA in comparison to thiazole orange. In order to use a uniform definition of juvenile platelets, the threshold for juvenile platelets was based on the IPF as determined by the Sysmex XN9000 analyzer, which is an internationally validated method in the clinic. An alternative analysis of juvenile platelets, based on the negative controls of both stainings, is presented in the supplements (Suppl. Fig. 3 ).
Thrombus formation in whole blood
Whole blood thrombus formation on microspots in a parallel-plate flow chamber was measured, basically as described before. 35 Patient blood samples were perfused through the chamber for 4 minutes at a wall-shear rate of 1600 s 
Results

P2Y 12 -inhibited platelets participate less in thrombus formation
In order to determine how platelets with non-responsive P2Y 12 receptors interact with responsive platelets in aggregation and thrombus formation, platelets from control subjects were treated with the clopidogrel active metabolite (CAM) and mixed in various proportions with untreated platelets. All platelets were also treated with aspirin, in order to mimic To investigate this further, we assessed how the CAM-treated platelets participated in thrombus formation on immobilized collagen under high-shear flow conditions. Therefore, the P2Y 12 -inhibited platelets were labelled with the red-exciting membrane label CellVue Maroon, whereas the untreated platelets were labeled with the green-exciting membrane label PKH26. This labeling did not affect platelet activation responses (data not shown).
Mixtures with 0%, 50% or 100% of CAM-treated platelets were added to red blood cells and plasma from the same donor to obtain reconstituted blood with different proportions of P2Y 12 -inhibited platelets. In comparison to reconstituted blood with solely uninhibited platelets, increasing proportions of CAM-treated platelets had limited impact on platelet adhesion to the collagen surface, but markedly suppressed the formation of large platelet aggregates (Suppl. Fig. 2 ). As a result, with CAM-treated platelets, surface area coverage ( Fig. 1C ) and mean thrombus size (Fig. 1D ) on collagen progressively decreased. Strikingly, with 50% of CAM-treated platelets, about 30% of the surface area coverage was occupied by the P2Y 12 inhibited platelets, while the remaining 70% was occupied by the P2Y 12 -responsive platelets. Together, these results indicate that P2Y 12 -inhibited platelets participate less in platelet aggregation and thrombus formation.
Gradual restoration of platelet aggregation in patients upon prasugrel offset
The offset phase of prasugrel medication was studied in 16 patients. The patients had a mean age of 59 ± 9 years (mean ± SD); three patients were diagnosed with type II diabetes mellitus (Suppl. Table 1 ). Blood samples taken at day 0 (i.e. last day of prasugrel intake)
showed a normal hematocrit of 0.435 ± 0.035 l/l and platelet count of 239 ± 81 x 10 9 /l. Subsequent blood samples were taken at days 1, 2, 5, and 30, and no noticeable changes in hematocrit or platelet count were observed.
Measurements of whole blood aggregation (Multiplate assay) showed a gradual increase in ADP-induced aggregation upon offset from days 2 to 30 ( Fig. 2A) . Interestingly, the aggregation response further increased at day 30 in comparison to day 5. Whole blood aggregation in response to arachidonic acid remained below the normal range ( (Fig. 3A) . In this test, the aggregation response with two ADP concentrations was near maximal already at day 5. Collagen-induced platelet aggregation also significantly improved, but only at later time points (Fig. 3B ). Control experiments in the presence of ticagrelor showed that the increase in aggregation during prasugrel offset was fully antagonized, confirming that the regained platelet reactivity was fully due to increased P2Y 12 receptor function ( Fig. 3A-B ).
Formation of a highly reactive population of juvenile platelets upon prasugrel offset
Based on earlier experiments with rats, 18 we expected during the offset phase of prasugrel Juvenile and old platelets were discriminated per blood sample, based on the negative control and the immature platelet fraction determined by Sysmex XN-9000 (Fig 5A) . For the majority of the patients, with one noticeable exception, the immature platelet fraction was in the normal range, with mean values of 3.6 ± 1.9%, and remaining constant per patient during the study (Fig. 5A ). Markedly, with either mRNA probe (thiazole orange or 5'Cy5-oligo-dT), the fraction of platelets with positive staining showed increased fibrinogen binding following ADP stimulation from day 2 on (Fig. 5B-C) . Fibrinogen binding (α IIb β 3 activation) of this juvenile platelet population continued to increase from day 5 to day 30. The difference between 5 and 30 days was significant for thiazole orange (p = 0.003), and was borderline significant for 5'Cy5-oligo-dT (p = 0.063), thus suggesting partial inhibition of these platelets even after 5 days offset. With either mRNA probe, the fraction of (older) platelets with negative staining was substantially lower in fibrinogen binding, with noticeable increase of activated integrins only from day 5 onwards (Fig. 5B-C) . The difference in fibrinogen binding between juvenile and older platelets was significant at all days (p < 0.001). These results were confirmed using an alternative analysis based on the appropriate negative controls (Suppl . Fig 3. ) Here again, the reactivity of juvenile platelets, expressed as activation ratio, was significantly higher in comparison to mature platelets at all days. Moreover, this analysis also shows the increasing reactivity of juvenile platelets over time for both stainings (Suppl. Fig 4A) . Additional platelet measurements with a limited number of patients showed that, after 12 days of prasugrel discontinuation, the reactivity of juvenile platelets was in between the day 5 and 30 values (Suppl. 
Gradual increase in thrombus size upon prasugrel offset
To investigate whether the increased reactivity of juvenile platelets after prasugrel cessation translates into enhanced thrombus formation, whole blood was perfused over microspots containing vWF/fibrinogen or type I collagen. 35 Given the major role of P2Y 12 signaling in thrombus build-up 36 , we determined thrombus size at the different time points. Regardless of the surface, at day 0 many single platelets and small aggregates were detected, whilst at later offset days larger aggregates were formed. From the recorded brightfield images it was apparent that the thrombi at days 5 and 30 displayed a more contracted morphology (Fig.   6A ). Quantification of the feature size showed on both microspots a progressive increase in mean thrombus size during offset ( Fig. 6B-C) . On the other hand, platelet adhesion to vWF/fibrinogen or collagen was not changed between day 0 and 30, as surface area coverage (by single platelets and aggregates) remained similar (Suppl. Fig. 5A-B) .
Staining of thrombi with AF647-labeled fibrinogen allowed assessment of integrin α IIb β 3 activation. On both the vWF/fibrinogen and collagen microspots, a marked increase in fibrinogen binding to the aggregated platelets was detected for the later blood samples (Suppl. Fig. 6A-B) . Addition of ticagrelor to the blood resulted in a nearly complete abolition of platelet aggregation at all offset days, but did not block platelet adhesion. With blood samples from a limited number of patients, staining with DiOC 6 made it possible to record zstacks by confocal microscopy for 3D visualization of the thrombi. This illustrated the gradual increase in thrombus size from day 0 to day 5 and 30 (Suppl. Fig. 6C ). Taken together, these results indicate that the accumulation of highly P2Y 12 -responsive, juvenile platelets upon prasugrel offset led to a gradual increase in formation of large-size thrombi.
Discussion
In this paper, we confirm earlier findings 7, 9, 15, 16, 37 that when treatment with an irreversible To determine how the increased reactivity of juvenile platelets translates into hemostasis, we studied thrombus formation under flow on two different adhesive surfaces using whole blood. Platelet deposition and aggregate formation on the vWF/fibrinogen and the collagen surfaces restored during the offset and was only maximal at day 30. The regained P2Y 12 activity was most apparent from thrombus size, with larger thrombi towards the end phase of the offset. This is in agreement with earlier work showing that signaling via P2Y 12 is crucial for thrombus formation and stabilization. 1, 36 Also others found a relative preponderance of thiazole orange-stained platelets in a thrombus.
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In recent years, it has been debated whether the termination of clopidogrel or prasugrel intake leads to a rebound effect of recurrent cardiovascular events, perhaps related to platelet hyper-reactivity. Several research groups did report a rebound effect within 90 days after cessation of clopidogrel, 13-17 while other researchers could not confirm this. far. 42, 43, 45 The present work may explain this ambiguity in clinical offset effects. On the one hand, cessation of clopidogrel or prasugrel medication will lead to the appearance of the newly formed platelets with uninhibited P2Y 12 receptors, which preferentially partake in thrombus formation. On the other hand, as shown in this study, at least during the first few days these juvenile platelets do not appear to be hyperactive, possibly due to residual receptor blockage at the megakaryocyte level. When tapering the medication, the prolonged time interval between two consecutive dosages will result in the alternative formation of uninhibited and inhibited platelets.
The present study has potential limitations, as we have investigated a relative small number of patients. Further, in our initial ex vivo studies we used the active metabolite of clopidogrel. Although prasugrel is a more potent P2Y 12 antagonist in comparison to clopidogrel, 5 we added the active metabolite of clopidogrel at concentrations high enough for maximal inhibition.
Patients on dual antiplatelet therapy who require surgery are recommended to stop prasugrel intake 7 days beforehand. 9 Our findings that prasugrel can still affect the reactivity of juvenile platelets during several days after treatment cessation does not plea for a shortening of this period. The compromised reactivity of juvenile platelets during the initial days of offset can contribute to a risk of bleeding upon surgery. When urgent surgery is required or when bleeding has to be controlled, platelet transfusions have shown to be effective in restoring haemostasis at 6 hours after a loading dose of prasugrel. 46 Altogether, the present study provides clinically relevant detailed insights into the mechanisms of prasugrel offset, and thereby provides better insight into the optimal treatment regimen of P2Y 12 inhibitors. 
Preparation of platelet-rich plasma, platelets and red cells
Platelet-rich plasma (PRP) was prepared by centrifuging citrate-anticoagulated blood at 240 g for 15 minutes at room temperature. Platelet-free plasma was obtained by centrifuging citrate-anticoagulated blood twice at 2630 g for 10 minutes. Washed platelets were prepared from ACD-anticoagulated blood, as described 2 , and were suspended in Hepes buffer pH 7.45 (10 mM Hepes, 136 mM NaCl, 2.7 mM KCl, 2 mM MgCl 2 , 0.1% glucose and 0.1% bovine serum albumin). Platelet counts were determined with a thrombocounter XP300
Sysmex analyzer (Sysmex, Chuo-ku Kobe, Japan).
Washed red blood cells were prepared by centrifuging citrate-anticoagulated blood at 240 g for 15 minutes at room temperature. 
Platelet aggregation
Aggregation of platelets in PRP was measured using a Chronolog aggregometer (Stago, Asnières sur Seine Cedex, France). 31 Preincubation with ticagrelor or vehicle medium was for 5 minutes at 37 °C. Aggregation of platelets in whole blood was measured by Multiplate impedance aggregometry (Roche Diagnostics, Basel, Switzerland) as described. 4 Aggregation was measured in response to ADP (6.4 µM), arachidonic acid (0.5 mM), collagen (3.2 µg/ml) or thrombin receptor-activating peptide SFLLRN (TRAP, 32 µM) at 37 °C during 6 minutes. Ticagrelor (1 µM) was added in vitro to block residual P2Y 12 activity, where indicated. Extent of platelet aggregation was assessed from the area under the impedance curve.
Flow cytometric analysis of platelet subpopulations
Flow cytometric measurements were performed on an Accuri C6 flow cytometer with CFlow formaldehyde and permeabilized (10 minutes) with 0.1% saponin. 5'-Cy5-oligo-dT (1 μM)
was incubated for 15 minutes at 37 °C. For all samples, 5'Cy5-oligo-dA (1 µM) was used as a negative control probe to check for specificity of the staining with 5'Cy5-oligo-dT. Color compensation was not required as fluorescent spectra did not overlap.
Thrombus formation in whole blood
Whole-blood thrombus formation on microspots in a parallel-plate flow chamber was measured, basically as described before. 7 Briefly, 0.5 μl microspots containing either collagen I (100 μg/ml) or fibrinogen (250 μg/ml) plus vWF (50 μg/ml) were perfused with citrate-anticoagulated whole blood, which was recalcified with 7.5 mM CaCl 2 and 3.75 mM Maroon (1.6 μM), whereas the vehicle-treated platelets were pre-labeled with the membrane probe PKH26 (0.8 μM). Both probes were not transferrable from cell to cell (data not shown).
The reconstituted whole blood was again co-perfused with 2MeS-ADP over collagen.
Microscopic DIC and confocal fluorescent images were taken using a Zeiss LSM7 microscope (Oberkochen, Germany).
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Statistical analysis
Statistical analysis was performed using the SPSS Statistics 22 package (Armonk, NY, USA). Statistical analysis was performed using a one-way-repeated-measures-ANOVA or with a Friedman test with a post hoc Wilcoxon signed rank test. Bonferroni correction was applied when comparing multiple groups. 
